文献速递生殖医学

模拟围青春期跨性别男性青年性别肯定治疗的小鼠模型:青春期抑制后给予睾酮

A mouse model mimicking gender-affirming treatment with pubertal suppression followed by testosterone in transmasculine youth.
PubMed 文献 · Hum Reprod · 2023-01-01

本研究用80只C57BL/6N雌鼠建立模型,先皮下植入3.6 mg GnRHa缓释剂抑制青春期,再每周注射0.45 mg睾酮庚酸酯6周;结果显示GnRHa组持续间情期、FSH、LH、雌二醇降低,T组和GnRHa+T组无动情周期、LH抑制、无黄体,但原始卵泡数未受影响。

要点

  • 3.6 mg GnRHa植入可抑制雌鼠青春期发育并维持持续间情期。
  • GnRHa后每周0.45 mg睾酮庚酸酯6周可模拟跨性别男性青年激素治疗。
  • GnRHa+T治疗未影响雌鼠原始卵泡数,提示卵巢储备未受影响。

核心结论

  • 3.6 mg GnRHa植入后每周0.45 mg睾酮庚酸酯可用于围青春期雌鼠,研究性别肯定激素治疗对跨性别男性青年的影响。
  • 该模型是首个模拟围青春期跨性别男性青年性别肯定激素治疗的小鼠模型。
  • GnRHa+T治疗未影响雌鼠原始卵泡数,提示卵巢储备未受影响。

研究设计与样本

  • 研究使用80只C57BL/6N雌鼠,每个实验组n=7只。
  • 实验一:26日龄雌鼠皮下植入3.6 mg GnRHa缓释剂,对照行假手术,术后3、9、21、28天处死。
  • 实验二:26日龄雌鼠皮下植入3.6 mg GnRHa 21天,随后每周注射0.45 mg睾酮庚酸酯6周,对照分别为假手术和芝麻油溶媒注射,末次注射后0.5周处死。

主要发现

  • GnRHa植入组持续间情期,FSH降低(P=0.0013)、LH降低(P=0.0082)、雌二醇降低(P=0.0155),子宫重量降低(P<0.0001)、卵巢重量降低(P=0.0002),植入后21天无黄体。
  • T单用组和GnRHa+T组在整个治疗期间无动情周期,T水平持续升高,LH水平抑制(P<0.0001),与对照相比无黄体(P<0.0001)。
  • T单用组和GnRHa+T组的配对卵巢重量较对照组和GnRHa单用组降低。

临床怎么用

  • 作者认为该模型为研究GnRHa-T治疗对生殖其他方面、其他器官系统和跨代效应提供了工具。
  • 作者指出将小鼠模型结果外推至人类生殖生理时需谨慎。

局限性

  • 将小鼠模型结果外推以反映人类生殖生理时需要谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can mice serve as a translational model to examine the reproductive consequences of pubertal suppression with GnRH agonist (GnRHa) followed by testosterone (T) administration, a typical therapy in peripubertal transmasculine youth? SUMMARY ANSWER: An implanted depot with 3.6 mg of GnRHa followed by T enanthate at 0.45 mg weekly can be used in peripubertal female mice for investigating the impact of gender-affirming hormone therapy in transmasculine youth. WHAT IS KNOWN ALREADY: There is limited knowledge available in transgender medicine to provide evidence-based fertility care, with the current guidelines being based on the assumption of fertility loss. We recently successfully developed a mouse model to investigate the reproductive consequences of T therapy given to transgender men. On the other hand, to our knowledge, there is no mouse model to assess the reproductive outcomes in peripubertal transmasculine youth. STUDY DESIGN, SIZE, DURATION: A total of 80 C57BL/6N female mice were used in this study, with n = 7 mice in each experimental group. PARTICIPANTS/MATERIALS, SETTING, METHODS: We first assessed the effectiveness of GnRHa in arresting pubertal development in the female mice. In this experiment, 26-day-old female mice were subcutaneously implanted with a GnRHa (3.6 mg) depot. Controls underwent a sham surgery. Animals were euthanized at 3, 9, 21 and 28 days after the day of surgery. In the second experiment, we induced a transmasculine youth mouse model. C57BL/6N female mice were subcutaneously implanted with a 3.6 mg GnRHa depot on postnatal day 26 for 21 days and this was followed by weekly injections of 0.45 mg T enanthate for 6 weeks. The control for the GnRH treatment was sham surgery and the control for T treatment was sesame oil vehicle injections. Animals were sacrificed 0.5 weeks after the last injection. The data collected included the day of the vaginal opening and first estrus, daily vaginal cytology, weekly and terminal reproductive hormones levels, body/organ weights, ovarian follicular distribution and corpora lutea (CL) counts. MAIN RESULTS AND THE ROLE OF CHANCE: GnRHa implanted animals remained in persistent diestrus and had reduced levels of FSH (P = 0.0013), LH (P = 0.0082) and estradiol (P = 0.0155), decreased uterine (P < 0.0001) and ovarian weights (P = 0.0002), and a lack of CL at 21 days after GnRHa implantation. T-only and GnRHa+T-treated animals were acyclic throughout the treatment period, had sustained elevated levels of T, suppressed LH levels (P < 0.0001), and an absence of CL compared to controls (P < 0.0001). Paired ovarian weights were reduced in the T-only and GnRHa+T groups compared with the control and GnRHa-only groups. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Although it is an appropriate tool to provide relevant findings, precaution is needed to extrapolate mouse model results to mirror human reproductive physiology. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this study describes the first mouse model mimicking gender-affirming hormone therapy in peripubertal transmasculine youth. This model provides a tool for researchers studying the effects of GnRHa-T therapy on other aspects of reproduction, other organ systems and transgenerational effects. The model is supported by GnRHa suppressing puberty and maintaining acyclicity during T treatment, lower LH levels and absence of CL. The results also suggest GnRHa+T therapy in peripubertal female mice does not affect ovarian reserve, since the number of primordial follicles was not affected by treatment. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Michigan Institute for Clinical and Health Research grants KL2 TR 002241 and UL1 TR 002240 (C.D.C.); National Institutes of Health grants F30-HD100163 and T32-HD079342 (H.M.K.); University of Michigan Office of Research funding U058227 (A.S.); American Society for Reproductive Medicine/Society for Reproductive Endocrinology and Infertility grant (M.B.M.); and National Institutes of Health R01-HD098233 (M.B.M.). The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core Facility was supported by the Eunice Kennedy Shriver NICHD/NIH grants P50-HD028934 and R24-HD102061. The authors declare that they have no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Dela Cruz C, Kinnear HM, Hashim PH, et al. A mouse model mimicking gender-affirming treatment with pubertal suppression followed by testosterone in transmasculine youth. Hum Reprod. 2023. PMID: 36484619. doi:10.1093/humrep/deac257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。